Clinical trial
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced…
NCT00089102 · Medical University of South Carolina, Other · Terminated
Key facts
| NCT number | NCT00089102 |
|---|---|
| Title | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer |
| Official title | Phase II Study of Gemcitabine and CPT-11 (Irinotecan) in Unresectable or Metastatic Renal Cell Carcinoma |
| Lead sponsor | Medical University of South Carolina, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, irinotecan hydrochloride |
| Enrollment | 9 |
| Start date | Sep 1, 2003 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Aug 5, 2004 |
| Last update posted | Jul 16, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: